Sponsor Pipeline

Guangzhou Virotech Pharmaceutical Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
6
Recruiting
1
Phase 3
3
Disease Areas
Active Trials by Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT07589244 A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC HCC Recruiting
Phase 2
NCT07589257 A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline… Diffuse Midline Glioma, H3 K27M-Mutant Recruiting
Phase 1/2
NCT07093814 A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma Glioblastoma Recruiting
Phase 1
NCT06046742 A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors Solid Tumor Recruiting
NCT06826313 A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors Solid Tumors Recruiting
NCT06368921 A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors Solid Tumor Recruiting
Disease Areas
Get alerts when Guangzhou Virotech Pharmaceutical Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free